Therapeutic Potential of Novel Twin Compounds Containing Tetramethylpyrazine and Carnitine Substructures in Experimental Ischemic Stroke

Table 2

Primary screening of neuroprotection and calculated median effective concentration (EC50) of 2-hydroxymethyl-3,5,6-trimethylpyrazine-carnitine ester twin compounds on oxygen-glucose deprivation- (OGD-) injured PC12 cells.

Compound	R	EC50 (nmol/L)
LR102	CH2CH3	>100
LR109	CH=CH-Ph	>100
LR120	CH3	>100
LR134	CH2CH2CH3	43.92 ± 10.93
LR137	CH(CH3)2	75.23 ± 13.36
LR140	(CH2)3CH3	50.88 ± 6.30
LR143	CH2CH(CH3)2	58.03 ± 11.36
LR146	(CH2)4CH3	>100
LR149	(CH2)7CH3	>100
LR152	(CH2)7CH=CH(CH2)7CH3	>100